Dr. Fabrizio Giordanetto


Fabrizio Giordanetto graduated with first class honors in Medicinal Chemistry in 2000 from University of Genoa, Italy. He completed his Ph.D. in Computational Medicinal Chemistry in 2003 at University of London, UK while working for the chemistry unit of Pharmacia (Pfizer) in Nerviano, Italy. In 2004 he joined the Medicinal Chemistry Department of AstraZeneca in Mölndal (Sweden) where he grew professionally to the position of Principal Scientist in Medicinal Chemistry and Preclinical Project Leader. Since 2013, he is Head of Medicinal Chemistry for Taros Gmbh, a research-based SME in Dortmund, Germany, where he leads medicinal chemistry activities and discovery projects. During his career, he worked on several drug discovery programs resulting in multiple clinical candidates spanning oncology, CNS and cardiovascular indications and >80 peer–reviewed publications, book chapters, and international patents.

In the INTEGRATE-ETN, Dr. Giordanetto is the main supervisor for ESR8. The research project of ESR8 will assess whether quorum sensing (QS) inhibition is a feasible approach for antibacterial purposes. The project aims to identify the first E. coli LsrK kinase inhibitors and evaluate their ability to impair bacterial growth based on QS interference (WP3).


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement No  642620
European Union